Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Adalimumab Biosimilar industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
LG Life Sciences/Mochida Pharmaceutical
Amgen
Pfizer
Boehringer Ingelheim
Samsung Bioepsis
Sandoz
Coherus Biosciences
Momenta Pharmaceuticals
Fujifilm Kyowa Kirin Biologics
AET BioTech
By Type:
Oral Solution
Tablet
By Application:
Online Pharmacy
Hospital Pharmacy
Retail Pharmacy
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Adalimumab Biosimilar Market Overview 2018-2029
-
1.1 China Adalimumab Biosimilar Industry Development Overview
-
1.2 China Adalimumab Biosimilar Industry Development History
-
1.3 China Adalimumab Biosimilar Industry Market Size (2018-2029)
-
1.4 China Adalimumab Biosimilar Market Analysis by Type from Production Side
-
1.4.1 China Adalimumab Biosimilar Production Volume, Production Value and Growth Rate of Oral Solution (2018-2029)
-
1.4.2 China Adalimumab Biosimilar Production Volume, Production Value and Growth Rate of Tablet (2018-2029)
-
1.5 China Adalimumab Biosimilar Market Analysis by Application from Consumption End
-
1.5.1 China Adalimumab Biosimilar Sales Volume, Sales Value and Growth Rate of Online Pharmacy (2018-2029)
-
1.5.2 China Adalimumab Biosimilar Sales Volume, Sales Value and Growth Rate of Hospital Pharmacy (2018-2029)
-
1.5.3 China Adalimumab Biosimilar Sales Volume, Sales Value and Growth Rate of Retail Pharmacy (2018-2029)
-
1.6 China Adalimumab Biosimilar Market Analysis by Region
-
1.6.1 North China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
Chapter 2 China Adalimumab Biosimilar Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Adalimumab Biosimilar Market Status and Competition at home and abroad in 2023
-
2.2.2 China Adalimumab Biosimilar Market Status and Competition Analysis in 2023
-
2.2.3 China Adalimumab Biosimilar Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Adalimumab Biosimilar Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Adalimumab Biosimilar Industry Development
Chapter 3 Adalimumab BiosimilarIndustry Chain Analysis
-
3.1 Adalimumab Biosimilar Industry Chain
-
3.2 Adalimumab Biosimilar Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Adalimumab Biosimilar Market
-
3.3 Adalimumab Biosimilar Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Adalimumab Biosimilar Market
Chapter 4 China Adalimumab Biosimilar Market, by Type
-
4.1 China Adalimumab Biosimilar Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Adalimumab Biosimilar Total Production Volume and Growth Rate from Production Side
-
4.5 China Adalimumab Biosimilar Production Volume and Growth Rate, by Type
-
4.5.1 China Adalimumab Biosimilar Production Volume and Growth Rate of Oral Solution
-
4.5.2 China Adalimumab Biosimilar Production Volume and Growth Rate of Tablet
Chapter 5 China Adalimumab Biosimilar Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Adalimumab Biosimilar Total Market Size and Growth Rate from Consumption End
-
5.5 China Adalimumab Biosimilar Market Size and Growth Rate, by Application
-
5.5.1 China Adalimumab Biosimilar Market Size and Growth Rate of Online Pharmacy
-
5.5.2 China Adalimumab Biosimilar Market Size and Growth Rate of Hospital Pharmacy
-
5.5.3 China Adalimumab Biosimilar Market Size and Growth Rate of Retail Pharmacy
Chapter 6 China Adalimumab Biosimilar Market, by Region
-
6.1 China Adalimumab Biosimilar Production Volume and Production Value, by Region
-
6.2 China Adalimumab Biosimilar Sales Volume and Sales Value, by Region
Chapter 7 North China Adalimumab Biosimilar Market Analysis
-
7.1 North China Adalimumab Biosimilar Market, by Type
-
7.2 North China Adalimumab Biosimilar Market, by Application
Chapter 8 Central China Adalimumab Biosimilar Market Analysis
-
8.1 Central China Adalimumab Biosimilar Market, by Type
-
8.2 Central China Adalimumab Biosimilar Market, by Application
Chapter 9 South China Adalimumab Biosimilar Market Analysis
-
9.1 South China Adalimumab Biosimilar Market, by Type
-
9.2 South China Adalimumab Biosimilar Market, by Application
Chapter 10 East China Adalimumab Biosimilar Market Analysis
-
10.1 East China Adalimumab Biosimilar Market, by Type
-
10.2 East China Adalimumab Biosimilar Market, by Application
Chapter 11 Northeast China Adalimumab Biosimilar Market Analysis
-
11.1 Northeast China Adalimumab Biosimilar Market, by Type
-
11.2 Northeast China Adalimumab Biosimilar Market, by Application
Chapter 12 Southwest China Adalimumab Biosimilar Market Analysis
-
12.1 Southwest China Adalimumab Biosimilar Market, by Type
-
12.2 Southwest China Adalimumab Biosimilar Market, by Application
Chapter 13 Northwest China Adalimumab Biosimilar Market Analysis
-
13.1 Northwest China Adalimumab Biosimilar Market, by Type
-
13.2 Northwest China Adalimumab Biosimilar Market, by Application
Chapter 14 Company Profiles
-
14.1 LG Life Sciences/Mochida Pharmaceutical
-
14.1.1 LG Life Sciences/Mochida Pharmaceutical Company Profile
-
14.1.2 LG Life Sciences/Mochida Pharmaceutical Adalimumab Biosimilar Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Amgen
-
14.2.1 Amgen Company Profile
-
14.2.2 Amgen Adalimumab Biosimilar Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Pfizer
-
14.3.1 Pfizer Company Profile
-
14.3.2 Pfizer Adalimumab Biosimilar Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Boehringer Ingelheim
-
14.4.1 Boehringer Ingelheim Company Profile
-
14.4.2 Boehringer Ingelheim Adalimumab Biosimilar Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Samsung Bioepsis
-
14.5.1 Samsung Bioepsis Company Profile
-
14.5.2 Samsung Bioepsis Adalimumab Biosimilar Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 Sandoz
-
14.6.1 Sandoz Company Profile
-
14.6.2 Sandoz Adalimumab Biosimilar Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Coherus Biosciences
-
14.7.1 Coherus Biosciences Company Profile
-
14.7.2 Coherus Biosciences Adalimumab Biosimilar Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Momenta Pharmaceuticals
-
14.8.1 Momenta Pharmaceuticals Company Profile
-
14.8.2 Momenta Pharmaceuticals Adalimumab Biosimilar Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Fujifilm Kyowa Kirin Biologics
-
14.9.1 Fujifilm Kyowa Kirin Biologics Company Profile
-
14.9.2 Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar Market Performance
-
14.9.3 Product&Service Introduction
-
14.10 AET BioTech
-
14.10.1 AET BioTech Company Profile
-
14.10.2 AET BioTech Adalimumab Biosimilar Market Performance
-
14.10.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Adalimumab Biosimilar Industry Research Conclusions
-
15.2 Adalimumab Biosimilar Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Adalimumab Biosimilar Industry Market Size (2018-2029)
-
Figure China Adalimumab Biosimilar Production Volume, Production Value and Growth Rate of Oral Solution (2018-2029)
-
Figure China Adalimumab Biosimilar Production Volume, Production Value and Growth Rate of Tablet (2018-2029)
-
Figure China Adalimumab Biosimilar Sales Volume, Sales Value and Growth Rate of Online Pharmacy (2018-2029)
-
Figure China Adalimumab Biosimilar Sales Volume, Sales Value and Growth Rate of Hospital Pharmacy (2018-2029)
-
Figure China Adalimumab Biosimilar Sales Volume, Sales Value and Growth Rate of Retail Pharmacy (2018-2029)
-
Figure North China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
Figure Central China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
Figure South China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
Figure East China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Adalimumab Biosimilar Market Size and Growth Rate from 2018-2029
-
Figure Adalimumab Biosimilar Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Adalimumab Biosimilar Market Share by Type in 2018
-
Figure China Adalimumab Biosimilar Market Share by Type in 2023
-
Figure China Adalimumab Biosimilar Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Adalimumab Biosimilar Production Volume and Growth Rate of Oral Solution (2018-2023)
-
Figure China Adalimumab Biosimilar Production Volume and Growth Rate of Tablet (2018-2023)
-
Figure China Adalimumab Biosimilar Market Share by Application in 2018
-
Figure China Adalimumab Biosimilar Market Share by Application in 2023
-
Figure China Adalimumab Biosimilar Total Market Size and Growth Rate from Consumption End
-
Figure China Adalimumab Biosimilar Market Size and Growth Rate of Online Pharmacy (2018-2023)
-
Figure China Adalimumab Biosimilar Market Size and Growth Rate of Hospital Pharmacy (2018-2023)
-
Figure China Adalimumab Biosimilar Market Size and Growth Rate of Retail Pharmacy (2018-2023)
-
Table China Adalimumab Biosimilar Production Volume by Region (2018-2023)
-
Table China Adalimumab Biosimilar Production Volume Share by Region (2018-2023)
-
Figure China Adalimumab Biosimilar Production Volume Share by Region (2018-2023)
-
Table China Adalimumab Biosimilar Production Value by Region (2018-2023)
-
Table China Adalimumab Biosimilar Production Value Share by Region (2018-2023)
-
Figure China Adalimumab Biosimilar Production Value Share by Region (2018-2023)
-
Table China Adalimumab Biosimilar Sales Volume by Region (2018-2023)
-
Table China Adalimumab Biosimilar Sales Volume Share by Region (2018-2023)
-
Figure China Adalimumab Biosimilar Sales Volume Share by Region (2018-2023)
-
Table China Adalimumab Biosimilar Sales Value by Region (2018-2023)
-
Table China Adalimumab Biosimilar Sales Value Share by Region (2018-2023)
-
Figure China Adalimumab Biosimilar Sales Value Share by Region (2018-2023)
-
Table North China Adalimumab Biosimilar Production Volume by Type (2018-2023)
-
Table North China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Figure North China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Table North China Adalimumab Biosimilar Sales Volume by Application (2018-2023)
-
Table North China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Figure North China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Table Central China Adalimumab Biosimilar Production Volume by Type (2018-2023)
-
Table Central China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Figure Central China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Table Central China Adalimumab Biosimilar Sales Volume by Application (2018-2023)
-
Table Central China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Figure Central China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Table South China Adalimumab Biosimilar Production Volume by Type (2018-2023)
-
Table South China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Figure South China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Table South China Adalimumab Biosimilar Sales Volume by Application (2018-2023)
-
Table South China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Figure South China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Table East China Adalimumab Biosimilar Production Volume by Type (2018-2023)
-
Table East China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Figure East China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Table East China Adalimumab Biosimilar Sales Volume by Application (2018-2023)
-
Table East China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Figure East China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Table Northeast China Adalimumab Biosimilar Production Volume by Type (2018-2023)
-
Table Northeast China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Figure Northeast China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Table Northeast China Adalimumab Biosimilar Sales Volume by Application (2018-2023)
-
Table Northeast China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Table Southwest China Adalimumab Biosimilar Production Volume by Type (2018-2023)
-
Table Southwest China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Figure Southwest China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Table Southwest China Adalimumab Biosimilar Sales Volume by Application (2018-2023)
-
Table Southwest China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Table Northwest China Adalimumab Biosimilar Production Volume by Type (2018-2023)
-
Table Northwest China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Figure Northwest China Adalimumab Biosimilar Production Volume Share by Type (2018-2023)
-
Table Northwest China Adalimumab Biosimilar Sales Volume by Application (2018-2023)
-
Table Northwest China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Adalimumab Biosimilar Sales Volume Share by Application (2018-2023)
-
Table LG Life Sciences/Mochida Pharmaceutical Company Profile
-
Table LG Life Sciences/Mochida Pharmaceutical Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Amgen Company Profile
-
Table Amgen Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Pfizer Company Profile
-
Table Pfizer Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Boehringer Ingelheim Company Profile
-
Table Boehringer Ingelheim Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Samsung Bioepsis Company Profile
-
Table Samsung Bioepsis Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Sandoz Company Profile
-
Table Sandoz Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Coherus Biosciences Company Profile
-
Table Coherus Biosciences Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Momenta Pharmaceuticals Company Profile
-
Table Momenta Pharmaceuticals Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table Fujifilm Kyowa Kirin Biologics Company Profile
-
Table Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
Table AET BioTech Company Profile
-
Table AET BioTech Adalimumab Biosimilar Revenue, Price and Gross (2018-2023)
-
